Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic, Nat. Med, vol.25, pp.547-553, 2019. ,
Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design, Annu. Rev. Immunol, vol.34, pp.635-659, 2016. ,
, Broadly Neutralizing HIV Antibodies Define a Glycan-Dependent Epitope on the Prefusion Conformation of gp41 on Cleaved Envelope Trimers. Immun, vol.40, pp.657-668, 2014.
From empiricism to rational design: A personal perspective of the evolution of vaccine development, Nat. Rev. Immunol, vol.14, pp.505-514, 2014. ,
Vaccines: An achievement of civilization, a human right, our health insurance for the future, J. Exp. Med, vol.216, pp.7-9, 2018. ,
Immunological correlates of protection from HIV infection and disease, Nat. Immunol, vol.7, pp.1281-1284, 2006. ,
Vaccines: Past, present and future, Nat. Med, vol.10, pp.5-11, 2005. ,
Liposomes Containing Monophosphoryl Lipid A: A Potent Adjuvant System For Inducing Antibodies To Heroin Hapten Analogs, vol.31, pp.2804-2810, 2013. ,
Recent progress in broadly neutralizing antibodies to HIV, Nat. Immunol, vol.19, pp.1179-1188, 2018. ,
Epitopes for neutralizing antibodies induced by HIV-1 envelope glycoprotein BG505 SOSIP trimers in rabbits and macaques, PLoS Pathog, vol.14, p.1006913, 2018. ,
HIV-1 Vaccines Based on Antibody Identification, B Cell Ontogeny, and Epitope Structure, Immun, vol.48, pp.855-871, 2018. ,
Reverse vaccinology 2.0: Human immunology instructs vaccine antigen design, J. Exp. Med, vol.213, pp.469-481, 2016. ,
HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design, Cell Host Microbe, vol.25, pp.59-72, 2019. ,
Prediction of VRC01 neutralization sensitivity by HIV-1 gp160 sequence features, PLoS Comput. Biol, p.1006952, 2019. ,
Phages and HIV-1: From display to interplay, Int. J. Mol. Sci, vol.13, pp.4727-4794, 2012. ,
Selection of Peptide Mimics of HIV-1 Epitope Recognized by Neutralizing Antibody VRC01, PLoS ONE, vol.10, p.120847, 2015. ,
Reverse Immunology Approach to Define a New HIV-gp41-Neutralizing Epitope, J. Immunol. Res, pp.1-13, 2019. ,
URL : https://hal.archives-ouvertes.fr/hal-02162037
Correlates of adjuvanticity: A review on adjuvants in licensed vaccines, Semin. Immunol, vol.39, pp.14-21, 2018. ,
Protein carriers of conjugate vaccines: Characteristics, development and clinical trials. Hum. Vaccines Immunother, vol.9, pp.2505-2523, 2013. ,
Mapping of conformational B cell epitopes within alpha-helical coiled coil proteins, Mol. Immunol, vol.34, pp.433-473, 1997. ,
Stapled HIV-1 Peptides Recapitulate Antigenic Structures and Engage Broadly Neutralizing Antibodies, Nat. Struct. Mol. Biol, vol.21, pp.1058-1067, 2014. ,
HIV-1 Vaccine Development: Constrained Peptide Immunogens Show Improved Binding to the Anti-HIV-1 gp41 MAb, Biochem, vol.42, pp.3214-3223, 2003. ,
Structural Basis of Enhanced Binding of Extended and Helically Constrained Peptide Epitopes of the Broadly Neutralizing HIV-1 Antibody 4E10, J. Mol. Biol, vol.365, pp.1533-1544, 2007. ,
Delivery of antigen using a novel mannosylated dendrimer potentiates immunogenicityin vitro andin vivo, Eur. J. Immunol, vol.38, pp.424-436, 2008. ,
Cellular uptake of the tat protein from human immunodeficiency virus, Cell, vol.55, pp.1189-1193, 1988. ,
TAT Modification of Alpha-Helical Anticancer Peptides to Improve Specificity and Efficacy, PLoS ONE, vol.10, p.138911, 2015. ,
Antigen targeting to dendritic cells elicits long-lived T cell help for antibody responses, J. Exp. Med, vol.203, pp.599-606, 2006. ,
, Vivo Targeting of Antigens to Maturing Dendritic Cells via the DEC-205 Receptor Improves T Cell Vaccination, vol.199, pp.815-824, 2004.
Tailored immunity by skin antigen-presenting cells. Hum. Vaccines Immunother, vol.11, pp.27-36, 2015. ,
Critical Role for Skin-Derived Migratory DCs and Langerhans Cells in TFH and GC Responses after Intradermal Immunization, J. Invest. Dermatol, vol.137, pp.1905-1913, 2017. ,
Control of TFH cell numbers: Why and how?, Immunol. Cell Biol, vol.92, pp.40-48, 2013. ,
Langerhans Cells Orchestrate TFH-Dependent Humoral Immunity, J. Investig. Dermatol, vol.137, pp.1826-1828, 2017. ,
, T cell help controls the speed of the cell cycle in germinal center B cells. Sci, vol.349, pp.643-646, 2015.
Immunological notes: XVII?XXIV, J. Pathol. Bacteriol, vol.29, pp.31-40, 1926. ,
Mechanisms of Action of Adjuvants, Front. Immunol, 2013. ,
Vaccine Adjuvants: Putting Innate Immunity to Work. Immun, vol.33, pp.492-503, 2010. ,
Evaluation of a new oil adjuvant for use in peptide-based cancer vaccination, Cancer Sci, vol.101, pp.2110-2114, 2010. ,
Peptides coupled to the surface of a kind of liposome protect infection of influenza viruses, vol.25, pp.4914-4921, 2007. ,
Phase I trial of a melanoma vaccine with gp100 (280-288) peptide and tetanus helper peptide in adjuvant: Immunologic and clinical outcomes, Clin. Cancer Res, vol.7, pp.3012-3024, 2001. ,
Adjuvants for human vaccines, Curr. Opin. Immunol, vol.24, pp.310-315, 2012. ,
Lipid vesicle size of an oral influenza vaccine delivery vehicle influences the Th1/Th2 bias in the immune response and protection against infection, vol.27, pp.3643-3649, 2009. ,
Vaccine delivery: A matter of size, geometry, kinetics and molecular patterns, Nat. Rev. Immunol, vol.10, pp.787-796, 2010. ,
Vaccine Adjuvant Systems containing monophosphoryl lipid A and QS-21 induce strong humoral and cellular immune responses against hepatitis B surface antigen which persist for at least 4 years after vaccination, vol.33, pp.1084-1091, 2015. ,
Development of Th1-mediated CD8 + effector T cells by vaccination with epitope peptides encapsulated in pH-sensitive liposomes, Vaccine, vol.19, pp.3608-3614, 2001. ,
Immunogenicity of synthetic HIV-1 V3 loop peptides by MPL adjuvanted pH-sensitive liposomes, Vaccine, vol.17, pp.1540-1548, 1999. ,
Elicitation of Robust Tier 2 Neutralizing Antibody Responses in Nonhuman Primates by HIV Envelope Trimer Immunization Using Optimized Approaches, vol.46, pp.1073-1088, 2017. ,
Rational Design of DNA-Expressed Stabilized Native-Like HIV-1 Envelope Trimers, Cell Rep, vol.24, pp.3324-3338, 2018. ,
An HIV-1 antibody from an elite neutralizer implicates the fusion peptide as a site of vulnerability, Nat. Microbiol, vol.2, p.16199, 2017. ,
Class-switched memory B cells remodel BCRs within secondary germinal centers, Nat. Immunol, vol.16, pp.296-305, 2015. ,
Selection of HIV-specific immunogenic epitopes by screening random peptide libraries with HIV-1-positive sera, J. Immunol, vol.162, pp.6155-6161, 1999. ,
Type-specific neutralization of the human immunodeficiency virus with antibodies to envencoded synthetic peptides, Proc. Natl. Acad. Sci, vol.85, pp.1932-1936, 1988. ,
Induction of broad cross-subtype-specific HIV-1 immune responses by a novel multivalent HIV-1 peptide vaccine in cynomolgus macaques, J. Immunol, vol.180, pp.2174-2186, 2008. ,
Protection of rhesus macaques against disease progression from pathogenic SHIV-89.6PD by vaccination with phage-displayed HIV-1 epitopes, Nat. Med, vol.7, pp.1225-1231, 2001. ,
Sequential Immunization with V3 Peptides from Primary Human Immunodeficiency Virus Type 1 Produces Cross-Neutralizing Antibodies against Primary Isolates with a Matching Narrow-Neutralization Sequence Motif, J. Virol, vol.80, pp.5552-5562, 2006. ,
Optimization of the EC26-2A4 Epitope in the gp41 Membrane Proximal External Region Targeted by Neutralizing Antibodies from an Elite Controller, AIDS Res. Hum. Retroviruses, vol.34, pp.365-374, 2018. ,
Enhancement of ?-Helicity in the HIV-1 Inhibitory Peptide DP178 Leads to an Increased Affinity for Human Monoclonal Antibody 2F5 but Does Not Elicit Neutralizing Responses in Vitro: IMPLICATIONS FOR VACCINE DESIGN, J. Biol. Chem, vol.277, pp.45811-45820, 2002. ,
An HIVgp41 vaccine protects CD4 central memory T cells in SHIV-infected macaques, Vaccine, vol.30, pp.6883-6891, 2012. ,
,
Neutralizing Antibodies Against a Specific Human Immunodeficiency Virus gp41 Epitope are Associated with Long-term Nonprogressor Status, vol.22, pp.122-132, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01599388
A Single Amino-Acid Change in a Highly Conserved Motif of gp41 Elicits HIV-1 Neutralization and Protects Against CD4 Depletion, Clin. Infect. Dis, vol.57, pp.745-755, 2013. ,
Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1, Nat. Med, vol.24, pp.857-867, 2018. ,
Consistent elicitation of cross-clade HIV-neutralizing responses achieved in guinea pigs after fusion peptide priming by repetitive envelope trimer boosting, PLoS ONE, vol.14, p.215163, 2019. ,
Complete functional mapping of infection-and vaccine-elicited antibodies against the fusion peptide of HIV, PLoS Pathog, vol.14, p.1007159, 2018. ,
Antibody Lineages with Vaccine-Induced Antigen-Binding Hotspots Develop Broad HIV Neutralization, Cell, vol.178, pp.567-584, 2019. ,
NK cytotoxicity against CD4 + T cells during HIV-1 infection: A gp41 peptide induces the expression of an NKp44 ligand, Proc. Natl. Acad. Sci, vol.102, pp.10981-10986, 2005. ,
Animal models in HIV-1 protection and therapy, Curr. Opin. HIV AIDS, vol.10, pp.170-176, 2015. ,
Non-Neutralizing Antibodies Directed against HIV and Their Functions, Front. Immunol, vol.8, p.1590, 2017. ,